Category: Uncategorized

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex®

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto®

Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin

Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

SUNSHINE BIOPHARMA GAINS FDA-EQUIVALENT CLEARANCE IN CANADA FOR DOMPERIDONE TO TREAT CANCER-RELATED NAUSEA